Welcome Guest
Home > Clinical Lymphoma Myeloma > Volume 7 |  Issue 4 > Article Abstract

Abstract
Back to TOC
References
X

Note:- Read as Author : Article Title : Source : Year : Publisher

    1.  Clynes RA,Towers TL,Presta LG : Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets : Nat Med : 2000 : .
    2.  Lee S,Sampson JH,Crotty LE : Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors : Proc Natl Acad Sci USA : 2000 : .
    3.  Yoneto T,Waki S,Takai T : A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resistance to blood-stage Plasmodium berghei XAT infection : J Immunol : 2001 : .
    4.  Chaperot L,Manches O,Lui G : In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas : Blood : 2003 : .
    5.  Grundy HO,Peltz G,Moore KW : The polymorphic Fc gamma receptor II gene maps to human chromosome 1q : Immunogenetics : 1989 : .
    6.  de Wit TP,Suijkerbuijk RF,Capel PJ : Assignment of three human high-affinity Fc gamma receptor I genes to chromosome 1, band q21.1 : Immunogenetics : 1993 : .
    7.  Bohen SP,Troyanskaya O,Alter O,de Wit TP,Suijkerbuijk RF,Capel PJ : IgG Fc receptors : Annu Rev Immunol : 2001 : .
    8.  Koene HR,Kleijer M,de Haas M : A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa : J Immunol : 1996 : .
    9.  Koene HR,Kleijer M,Algra J : Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype : Blood : 1997 : .
    10.  Wu J,Edberg JC,Redecha PB : A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease : J Clin Invest : 1997 : .
    11.  Xu L,Santos DD,Hatjiharissi E : Individuals expressing FcgRIIIA-158 V/V and V/F show increased NK cell surface expression of FcgRIIIA (CD16), rituximab binding, and demonstrate higher levels of ADCC activity in response to rituximab : Blood : 2005 : .
    12.  Cartron G,Dacheux L,Salles G : Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene : Blood : 2002 : .
    13.  Cartron G,Dacheux L,Salles G,Wilson WH,Gutierrez M,O’ Connor P,Golay J,Zaffaroni L,Vaccari T : Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma : J Clin Oncol : 2003 : .
    14.  Hansen M,Treon SP,Branagan AR : Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom’s macroglobulinemia : J Clin Oncol : 2005 : .
    15.  Campbell D,Anolik JH,Felgar RE : The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus : Arthritis Rheum : 2003 : .
    16.  Kim DH,Jung HD,Kim JG : FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma : Blood : 2006 : .
    17.  Warmerdam PA,van de Winkel JG,Gosselin EJ : Molecular basis for a polymorphism of human Fc gamma receptor II (CD32) : J Exp Med : 1990 : .
    18.  Warmerdam PA,van de Winkel JG,Vlug A : A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding : J Immunol : 1991 : .
    19.  Warmerdam PA,Parren PW,Boeije LC : On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets.Analysis of a functional polymorphism to human IgG2 : J Clin Invest : 1992 : .
    20.  Modali R,Flinn IW,Farag SS : Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia : Blood : 2004 : .
    21.  van der Pol WL,Jansen MD,Sluiter WJ : Evidence for non-random distribution of Fcgamma receptor genotype combinations : Immunogenetics : 2003 : .
    22.  Zhu S,Foster CB,Lehrnbecher T : Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations : Blood : 1999 : .
    23.  Hong K,Shields RL,Namenuk AK : High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R : J Biol Chem : 2001 : .
    24.  Presta LG,Shields RL,Namenuk AK : Engineering therapeutic antibodies for improved function : Biochem Soc Trans : 2002 : .
    25.  Link BK,Wang SY,Bowles JA : Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab : Blood : 2006 : .
E-mail this article
X

Fields marked with an asterisk * are mandatory.

* Your Name:
* Your Email:
* Friend's Name:
* Friend's Email:
Message:
 
Send CC to self
 
 
Add to Favorites
X
  • Volume Number 7
  •  Issue 4
    • Cover Date: January 01, 2007


Genetic Linkage of FcγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy


Authors: Evdoxia Hatjiharissi, Mark Hansen, Daniel Ditzel Santos, Lian Xu, Xavier Leleu, Elizabeth W. Dimmock, Allen W. Ho, Zachary R. Hunter, Andrew R. Branagan, Christopher J. Patterson, Alexandros Kortsaris, Sigitas verselis, Edward Fox, Steven P. Treon

Background: Polymorphisms in FcγRIIa and FcγRIIIa receptors are associated with responses to the CD20-directed immunoglobulin G1 (IgG1) monoclonal antibody rituximab among patients with indolent lymphoma. At odds with the aforementioned clinical observations has been the finding that IgG1 binding is impacted by polymorphisms in FcγRIIla but not FcγRIIa. One possibility for this discrepancy might involve linkage of polymorphisms between FcγRIIa and FcγRIIla. Materials and Methods: As such, we performed allele-specific polymerase chain reaction and directed sequencing of the genomic DNA coding region of FcγRIIa and FcγRIIla for 52 healthy individuals. Results: Two common polymorphisms were observed for FcγRIIa (at positions 27 and 131) and FcγRIIla (at positions 48 and 158). Importantly, we observed linkage among polymorphisms within and between FcγRIIa and FcγRIIla, including the expression of histidine at FcγRIIa-131 and valine at FcγRIIla, both of which are associated with enhanced responses to rituximab. The results of these studies demonstrate that there is wide linkage within and between polymorphisms in FcγRIIa and FcγRIIla and might provide an explanation for why polymorphisms at FcγRIIa are associated with rituximab responses despite a lack of impact on IgG1 binding. Conclusion: Knowledge of such linkages could facilitate the development of diagnostic tests aimed at identifying patients who might be more suitable for treatment with rituximab and possibly other therapeutic antibodies.

Keywords: CD16, CD32, Fcγ receptors, Polymorphisms, Rituximab


  1. https://www.ceteresopolitano.org/
  2. https://www.crossingstoronto.com/
  3. https://www.jediism.org/
  4. https://www.badenumc.org/
  5. https://www.johnsevierchapter.org/
  6. https://www.trinitychapelmn.org/
  7. https://www.photogearnews.com/
  8. https://www.alz-nova.org/
  9. https://www.cigjournals.com/
  10. https://summa-edu.com/
  11. https://cpawilmingtonnc.org/
  12. https://bimometals.com/
  13. https://sosenvironmental.com/
  14. https://thefriary.org/
  15. https://post5theatre.org/
  1. Pengeluaran SDY